These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 19995325)

  • 1. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN; Friedman HS; Perfetto EM
    Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
    Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
    Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
    Davis SL; Delgado G; McKinnon PS
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
    Wenisch C; Krause R; Széll M; Laferl H
    Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
    Simoens S
    Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A; Holman A; Evers T
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.
    Warren DK; Shukla SJ; Olsen MA; Kollef MH; Hollenbeak CS; Cox MJ; Cohen MM; Fraser VJ
    Crit Care Med; 2003 May; 31(5):1312-7. PubMed ID: 12771596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia].
    Pişkin N; Aydemir H; Oztoprak N; Akduman D; Celebi G; Seremet Keskin A
    Mikrobiyol Bul; 2009 Oct; 43(4):597-606. PubMed ID: 20084912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study.
    Fine MJ; Hough LJ; Medsger AR; Li YH; Ricci EM; Singer DE; Marrie TJ; Coley CM; Walsh MB; Karpf M; Lahive KC; Kapoor WN
    Arch Intern Med; 1997 Jan; 157(1):36-44. PubMed ID: 8996039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia.
    Coley CM; Li YH; Medsger AR; Marrie TJ; Fine MJ; Kapoor WN; Lave JR; Detsky AS; Weinstein MC; Singer DE
    Arch Intern Med; 1996 Jul; 156(14):1565-71. PubMed ID: 8687265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
    McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
    Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.